Examination about the combination medical treatment of the antihypertensive drug which assumed extraneous blood pressure an index

Examination about the combination medical treatment of the antihypertensive drug which assumed extraneous blood pressure an index - The combination medical treatment of the antihypertensive drug which assumed extraneous blood pressure an index

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007156

Enrollment

Registered

2012-04-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

First we prescribe olmesartan medoxomil for hypertension patient for 12 weeks. We continue the therapy more for 16 weeks when it works well. However, when the efficacy of the drug is not enough, we ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: essential hypertension

Exclusion criteria

Exclusion criteria: secondary hypertension angina pectoris severe heart disease severe diabetic mellitus (HbA1c > 10%) severe liver disease (AST or ALT > 100U/L) malignancy allergy for olmesartan medoxomil or azelnidipine

Design outcomes

Primary

Measure	Time frame
Achievement rate of antihypertensive therapy which assumed extraneous blood pressure in JSH2009 an index	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026